2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1154

Use of Including Serum Ferritin and Heme Oxygenase 1 in the Yamaguchi’s Classification for Adult-Onset Still’s Disease: A Multicenter Retrospective Study
Abstract Number: 1155

Impact of Adalimumab on Immunosuppressant Use in Patients with Active and Inactive Non-Infectious Intermediate, Posterior, or Pan-Uveitis in the Ongoing Open Label Study: Visual-III
Abstract Number: 1156

Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data
Abstract Number: 1157

Hypocomplementemia Is Closely Related to IgG Subclasses Other Than IgG4 in IgG4-Related Disease
Abstract Number: 1158

Treatment of Non-Infectious Uveitis: A Comparative Long-Term Study between Biologic Therapy with Adalimumab and Two Conventional Disease-Modifying Antirheumatic Drugs
Abstract Number: 1159

National Recommendations on the Use of Immunomodulatory Drugs in Patients with NON-Infectious NON-Malignant Anterior Uveitis
Abstract Number: 1160

Increased Incidence of Upper and Lower Gastrointestinal Events in Patients with Sarcoidosis: A Population-Based Cohort Study
Abstract Number: 1161

Clinical Characteristics of Ocular Sarcoidosis: A Population Based Study 1976-2013
Abstract Number: 1162

Impact of Bone Localization on the Prognostic of Langerhans Cell Histiocytosis: A Monocentric Retrospective Study
Abstract Number: 1163

A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects
Abstract Number: 1164

Spectrum of Skin Eruption and Histological Findings in Adult-Onset Still’s Disease and Significance of Atypical Persistent Skin Eruptions
Abstract Number: 1165

Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan
Abstract Number: 1166

Systemic Degos Disease: Long Term Survival on Combined Therapy with Eculizumab and Treprostinil
Abstract Number: 1167

Phenotypical Features of Patients with Rheumatologic Manifestations of Common Variable Immunodeficiency
Abstract Number: 1168

Eosinophilic Fasciitis: Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].